Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3850 [177Lu]-oxodotreotide in the treatment of gastroenteropancreatic neuroendocrine tumors – Patient profile in the REAL LU study (pRospective obsErvationAL study to assess the effectiveness and outcomes associated with LUtathera)

Introduction: Somatostatin (SST) receptor (SSTR) radioligand therapy is an option for highly SSTR-expressing gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The REAL LU study [NCT04727723] is evaluating the effectiveness of [177Lu]-oxodotreotide (LuO) in unresectable/metastatic, progressive, SSTR-expressing, Grade (G)1 or G2 GEP-NETs in clinical practice.

Conference:

Presenting Author:

Authors: Lastoria S, Tafuto S, Rodari M, Lania A, Sansovini M,

Keywords: REAL LU, GEP-NET, RLT, neuroendocrine tumor, radioligand therapy, [177Lu]-oxodotreotide,

#3635 Non-responders to Peptide Receptor Radionuclide Therapy (PRRT) – A single center retrospective analysis

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) has become the standard of care for patients (pts) with positive somatostatin receptor image, grade (G)1/2 gastrointestinal (GI) neuroendocrine tumors (NETs) after Somatostatin Analogues (SSAs) failure.

Conference:

Presenting Author: Laffi A

Authors: Laffi A, Rodari M, Lania A, Zerbi A, Elisabetta L,

Keywords: PRRT, neuroendocrine tumor, NET, Nuclear Medicine,

#651 Additional Value of New Molecular Imaging Tracers in the Detection of Recurrent/Residual Disease in Patients with Neuroendocrine Tumors

Introduction: Recent studies have proposed new molecular imaging tracers, such as 18F-DOPA and 68Ga-DOTANOC, for the detection of recurrent/residual neuroendocrine tumors (NET) in case of negative conventional imaging modalities.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Verga U, Filopanti M, Fugazzola L, Rodari M, Lopci E,

Keywords: 18F-DOPA, 68Ga-DOTANOC, recurrent/residual NET,